CheckMyRecalls

Ascend Laboratories, LLC recalls

12 recall notices naming Ascend Laboratories, LLC since January 2025, in United States. The most recent was published 28 Oct 2026.

Latest recalls (12)

  1. Ascend Laboratories, LLC recalls Amlodipine and Olmesartan Medoxomil TabletsFDAOut of specification due to dissolution.
  2. Ascend Laboratories, LLC recalls Dabigatran Etexilate CapsulesFDAFailed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total…
  3. Ascend Laboratories, LLC recalls Dabigatran etexilate CapsulesFDAFailed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II,…
  4. Ascend Laboratories, LLC recalls Amlodipine and Olmesartan Medoxomil TabletsFDAFailed Dissolution Specifications; Olmesartan Medoxomil content below specifications
  5. Ascend Laboratories, LLC recalls Minocycline Hydrochloride Extended-Release TabletsFDAFailed Dissolution Specifications: An out-of-specification (OOS) result was observed during the 9th month of dissolution test analysis
  6. Ascend Laboratories, LLC recalls Amlodipine and Olmesartan Medoxomil TabletsFDAFailed Dissolution Specifications: Olmesartan Medoxomil content below specifications
  7. Ascend Laboratories, LLC recalls Ascend LaboratoriesFDAFailed Dissolution Specifications
  8. Ascend Laboratories, LLC recalls Atorvastatin Calcium Tablets USPFDAFailed Dissolution Specifications
  9. Ascend Laboratories, LLC recalls Aripiprazole TabletsFDASuperpotent drug
  10. Ascend Laboratories, LLC recalls Amlodipine and Olmesartan Medoxomil TabletsFDAFailed Dissolution Specifications: low dissolution results
  11. Ascend Laboratories, LLC recalls Rizatriptan Benzoate TabletsFDACGMP Deviations: detection of N-nitroso-dimethyl-rizatriptan impurity, above the FDA recommended acceptable intake limit.
  12. Ascend Laboratories, LLC recalls Cephalexin for Oral SuspensionFDAFailed Impurities/Degradation Specifications An out-of-specification result was observed in the related substance test at the sixth month of…